Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

SANOFI : Former Sanofi employees convicted of bribery in Germany

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/03/2014 | 07:24pm CEST

FRANKFURT (Reuters) - A German court convicted two former employees of Sanofi-Aventis on bribery charges 10 months ago and imposed a fine on the French drugmaker last year, prosecutors said on Monday following a newspaper report.

News of the 28 million euro ($39 million) fine coincides with heightened scrutiny of Big Pharma's sales practices after a bribery scandal in China hit business there last year.

Further investigations are ongoing, a spokesman for prosecutors in the northern German town of Verden said, confirming a report by German daily newspaper Frankfurter Allgemeine Zeitung, but they declined to say whether these were related to Sanofi or to its employees.

The spokesman said an investigation of the former Sanofi employees found that they had made illicit payments to a consultancy advising one of the drugmaker's clients between 2007 and 2010 to win more orders from the client, a pharmaceuticals dealer.

"Sanofi was unfairly given preference because of this," he said.

He declined to provide details on who the client was or which markets it operated in. He also did not name the former Sanofi employees or the consultant.

A court in the town of Winsen handed the two former employees of Sanofi suspended sentences for bribery in business transactions in May 2013, the spokesman said. They both worked with Sanofi's sales force and were not senior managers.

The Winsen court also ordered that punishment be meted out to the owner of the consultancy, but that judgment was not yet final due to a pending complaint against the ruling.

The bribery investigation has not come to light until now because the suspects were sentenced via a simplified legal process that under German law allows courts to try some crimes without a courtroom trial.

The court's ruling also resulted in a 28 million euro fine for Sanofi. A spokeswoman for Sanofi-Aventis Deutschland GmbH confirmed the company had to pay that sum in connection with the case against the two former employees.

"For Sanofi the matter is closed," the spokeswoman said, referring to the Winsen court's rulings. She added the company had cooperated with authorities during the investigation and had since further tightened its compliance system.

Sanofi acquired Aventis in 2004, creating Sanofi-Aventis. In 2011, the company simplified its name to Sanofi.

(Reporting by Maria Sheahan and Frank Siebelt; Additional reporting by Natalie Huet in Paris; Writing by Marilyn Gerlach; editing by Mike Collett-White)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01:48aWISETECH GLOBAL (ASX : WTC) Acquires Three Leading Logistics Solution Providers ..
AQ
04/21SANOFI AVENTIS PAKISTAN : Board of directors meeting of Sanofi - Aventis Pakista..
AQ
04/20Generics group Alvogen puts Eastern European operations up for sale - sources
RE
04/20SANOFI : Advent International enters into exclusive negotiations to acquire Zent..
AQ
04/19UN HEALTH AGENCY : Dengue vaccine shouldn't be used widely
AQ
04/19SANOFI : Advent, near deal to buy Sanofi`s Zentiva, lays out big goals for gener..
AQ
04/19SANOFI : Advent International to acquire Zentiva, Sanofi`s European generics bus..
AQ
04/18SANOFI : in talks with Advent to sell its European generics arm for 1.9bn
AQ
04/18SANOFI : CFO Jerome Contamine to Depart Later This Year
DJ
04/18SANOFI : in talks with Advent to sell its European generics unit for €1.9bn
AQ
More news
News from SeekingAlpha
04/20PORTFOLIO STRATEGY REPORT : Why Investors Should Build Shares In Bioscience Stoc.. 
04/20Now See Wall Street's 38 'Safer' International Dividend WallStars For April 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/18Catalyst Pipeline Portfolio Updates - Strong Start To For The Portfolio 
04/17Evelo Biosciences Files For U.S. IPO 
Financials (€)
Sales 2018 35 107 M
EBIT 2018 8 633 M
Net income 2018 4 940 M
Debt 2018 14 433 M
Yield 2018 4,71%
P/E ratio 2018 16,06
P/E ratio 2019 14,21
EV / Sales 2018 2,75x
EV / Sales 2019 2,58x
Capitalization 81 998 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 79,1 €
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-9.14%100 746
JOHNSON & JOHNSON-8.71%339 783
PFIZER0.86%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY4.55%158 571